Log in
NASDAQ:PTLA

Portola Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.03
0.00 (0.00 %)
(As of 07/16/2020)
Add
Compare
Today's Range
$18.03
Now: $18.03
$18.03
50-Day Range
$18.03
MA: $18.03
$18.03
52-Week Range
$5.31
Now: $18.03
$31.73
VolumeN/A
Average Volume3.17 million shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
Read More
Portola Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$116.64 million
Book Value$1.67 per share

Profitability

Net Income$-290,660,000.00
Net Margins-232.73%

Miscellaneous

Employees324
Market Cap$1.42 billion
Next Earnings DateN/A
OptionableOptionable

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Portola Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Portola Pharmaceuticals
.

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analyst estimates of $33.88 million. Portola Pharmaceuticals had a negative return on equity of 267.86% and a negative net margin of 232.73%. The company's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.02) earnings per share.
View Portola Pharmaceuticals' earnings history
.

What price target have analysts set for PTLA?

7 brokers have issued 1 year price targets for Portola Pharmaceuticals' shares. Their forecasts range from $17.00 to $44.00. On average, they expect Portola Pharmaceuticals' stock price to reach $28.17 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price.
View analysts' price targets for Portola Pharmaceuticals
.

Who are some of Portola Pharmaceuticals' key competitors?

What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Exelixis (EXEL), Amarin (AMRN), Geron (GERN), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN).

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the following people:
  • Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)
  • Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)
  • Mr. J. Scott Garland M.B.A., MBA, Pres & CEO (Age 50)
  • Cara Miller, VP of Investor Relations and Corp. Communications
  • Mr. John B. Moriarty Jr., Exec. VP, Gen. Counsel & Sec. (Age 51)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.93%), Goldman Sachs Group Inc. (4.57%), Water Island Capital LLC (2.99%), ARP Americas LP (2.81%), CNH Partners LLC (1.90%) and Healthcare of Ontario Pension Plan Trust Fund (1.80%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Hollings Renton and Mardi Dier.
View institutional ownership trends for Portola Pharmaceuticals
.

Which institutional investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management Fund Advisors L.P., New York State Common Retirement Fund, Macquarie Group Ltd., Jacobs Levy Equity Management Inc., Two Sigma Advisers LP, State of Wisconsin Investment Board, Bank of America Corp DE, and Russell Investments Group Ltd..
View insider buying and selling activity for Portola Pharmaceuticals
.

Which institutional investors are buying Portola Pharmaceuticals stock?

PTLA stock was bought by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Goldman Sachs Group Inc., ARP Americas LP, CNH Partners LLC, Healthcare of Ontario Pension Plan Trust Fund, Barclays PLC, Bardin Hill Management Partners LP, and Gabelli Funds LLC.
View insider buying and selling activity for Portola Pharmaceuticals
.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $18.03.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $1.42 billion and generates $116.64 million in revenue each year. The biopharmaceutical company earns $-290,660,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis. Portola Pharmaceuticals employs 324 workers across the globe.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is www.portola.com.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.